Goldman Sachs initiated coverage of Teladoc (TDOC) with a Buy rating and $14 price target The company’s integrated care business should generate continued membership and revenue growth, led by the Chronic Care Segment, the analyst tells investors in a research note. In addition, the firm believes Teladoc’s more targeted BetterHelp strategy should result in membership and utilization bottoming in the end of 2025 with growth thereafter. It sees growth acceleration in 2026 driving the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TDOC:
- Teladoc call volume above normal and directionally bullish
- Teladoc price target raised to $12 from $10 at Deutsche Bank
- Teladoc price target lowered to $14 from $17 at Canaccord
- Teladoc price target raised to $11 from $10 at Cantor Fitzgerald
- Teladoc price target lowered to $8 from $9 at TD Cowen
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
